CF PHARMTECH, INC.

CF PharmTech, Inc.

Equities

2652

CNE1000074R9

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 08:08:19 09/03/2026 GMT			5-day change	1st Jan Change
29.50 ^HKD	-13.39%		-24.36%	-15.71%

03-09	CF PharmTech Gets China Approval for Clinical Trial of Allergic Rhinitis Nasal Spray	MT
03-09	Cf Pharmtech announces approval of clinical trial application for olopatadine hydrochloride, mometasone furoate monohydrate nasal spray	RE

CF PharmTech to Join Hang Seng Composite Index

Published on 02/16/2026 at 05:23 am GMT

MT Newswires

Lock

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

© MT Newswires - 2026

Latest news about CF PharmTech, Inc.

03-09	CF PharmTech Gets China Approval for Clinical Trial of Allergic Rhinitis Nasal Spray	MT
03-09	Cf Pharmtech announces approval of clinical trial application for olopatadine hydrochloride, mometasone furoate monohydrate nasal spray	RE
02-24	CF PharmTech says NMPA accepted IND application for ICF004	RE
02-24	CF PharmTech Says Chinese Regulators Accept Investigational New Drug Application for ICF004	MT
02-23	CF PharmTech , Inc. Announces Acceptance of Ind Application for ICF004 by the National Medical Products Administration of the People's Republic of China	CI
02-16	CF PharmTech to Join Hang Seng Composite Index	MT
01-30	China Regulator Accepts CF PharmTech's Budesonide Nasal Spray Marketing Application	MT
01-30	CF PharmTech Inc says NMPA accepts marketing authorization application for Budesonide Nasal Spray	RE
01-29	CF PharmTech, Inc. Announces Acceptance of Marketing Authorization Application for Budesonide Nasal Spray by the National Medical Products Administration	CI
12-30	CF PharmTech, Inc. commences an Equity Buyback Plan for 30,222,358 shares, representing 7.34% of its issued share capital, under the authorization approved on December 16, 2025.	CI
12-24	CF PharmTech's Respiratory Drug Project Selected for Jiangsu Innovative Biologics Program	MT
12-23	Cf Pharmtech, Inc. Announces Selection of A Company-Led Project into the 2025 Jiangsu Provincial Major Science and Technology Program	CI
12-17	CF PharmTech says NMPA accepts clinical trial application for olopatadine hydrochloride and mometasone furoate monohydrate nasal spray	RE
12-17	CF PharmTech, Inc. Announces Clinical Trial Application for Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray Accepted by NMPA	CI
11-26	CF PharmTech Launches H-Share Full Circulation Plan; Shares Slip 2%	MT

Chart CF PharmTech, Inc.

Duration

Period

Chart CF PharmTech, Inc.

2652: Dynamic Chart

Company Profile

Employees

574

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Stock Market
Stock Market News
CF PharmTech to Join Hang Seng Composite Index

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!

BENEFIT NOW